Welcome to our dedicated page for Addex Therapeutics SEC filings (Ticker: ADXN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Addex Therapeutics Ltd (ADXN), a clinical-stage pharmaceutical company focused on small-molecule allosteric modulators. As a foreign issuer listed on the NASDAQ Capital Market, Addex Therapeutics reports to the SEC using forms such as Form 20-F for annual reports and Form 6-K for current information.
Recent Form 6-K filings for Addex Therapeutics include press releases, unaudited interim condensed consolidated financial statements, and management’s discussion and analysis of financial condition and results of operations. These documents are often incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, as disclosed in the filings. The company’s reports also emphasize that its business faces significant risks and refer readers to risk factors discussed in its Form 20-F.
On Stock Titan, Addex Therapeutics filings are updated from the SEC’s EDGAR system, and AI-generated summaries can help explain the structure and key points of lengthy documents. Users can review annual disclosures on Form 20-F, interim information and press releases furnished on Form 6-K, and other registered offerings referenced in the company’s F-3 and S-8 statements.
For those analyzing ADXN, this filings page offers a structured view of Addex Therapeutics’ regulatory history, including financial statement presentations, discussions of results of operations, and risk disclosures that the company highlights as important to understanding its business and prospects.
Addex Therapeutics reported that its spin-out company Neurosterix remains on track to complete a Phase 1 clinical study of NTX-253 for schizophrenia in Q2 2026. NTX-253 is an oral, potent, selective positive allosteric modulator of the muscarinic M4 receptor, aiming to treat schizophrenia by indirectly modulating dopamine signaling.
The Phase 1 program includes single ascending dose and multiple ascending dose components in healthy adults and adults with stable schizophrenia, assessing safety, tolerability, pharmacokinetics, food effects and cerebrospinal fluid exposure. Neurosterix, spun out of Addex in April 2024, raised $65 million in Series A financing, and Addex retains a 20% equity interest in the company.
Addex Therapeutics reported new preclinical data showing its novel GABAB positive allosteric modulator (PAM) produced robust anti-tussive, or cough-suppressing, activity in a non-human primate chronic cough model. The candidate significantly reduced citric acid-induced cough frequency with efficacy similar to baclofen.
Previously reported guinea pig data showed the same GABAB PAM reduced cough frequency, increased cough latency and did not show tolerance after sub-chronic treatment, with antitussive effects appearing superior to nalbuphine, baclofen, codeine and a P2X3 inhibitor. The compound also demonstrated better tolerability and a wider therapeutic margin than nalbuphine, baclofen or codeine, and similar tolerability to a P2X3 inhibitor based on respiratory rate.
Addex is advancing this GABAB PAM program for chronic cough alongside other allosteric modulator programs, including its lead candidate dipraglurant for brain injury recovery and partnered GABAB PAM development in substance use disorders.
Addex Therapeutics Ltd. director and chief medical officer Roger Mills reported his initial holdings. He directly owns 785,976 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options over 50,000 shares, exercisable at $0.0640 per share.
The options began vesting in equal monthly installments over four years from the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars using an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. director Vincent Michael Lawton has filed a Form 3 reporting his initial beneficial ownership in the company. He holds 2,507,987 shares of Common Stock listed on the SIX Swiss Exchange and a stock option award over 501,598 shares of Common Stock.
The stock options carry an exercise price of $0.064 per share, based on a CHF-to-USD exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026. These options began vesting in equal monthly installments over a four-year period starting January 8, 2024 and expire on January 7, 2034.
Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares. These options are rights to buy shares at fixed prices and represent existing compensation grants, not new share purchases or sales.
The filing lists several option grants with exercise prices of $0.1660, $0.0550, and $0.0640 per share, expiring between 2027 and 2034. According to the footnotes, each option gives the right to buy one ADXN share, vesting in equal monthly installments over four years, and the exercise prices are reported in U.S. dollars using a $1.2769 per CHF $1.00 exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. executive Mikhail Kalinichev filed an initial ownership report showing his equity stake in the company. He directly holds 306,765 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 200,000 shares at an exercise price of $0.0640 per share. The option is exercisable from August 1, 2024, vests in equal monthly installments over four years, and expires on January 7, 2034. Each option entitles him to purchase one ADXN share on SIX Swiss Exchange.
Addex Therapeutics Ltd. director Raymond George Hill filed an initial ownership report showing his equity position in the company. He holds 1,365,532 shares of Common Stock listed on the SIX Swiss Exchange and a stock option over 273,107 shares of Common Stock.
The stock option has an exercise price of $0.0640 per share, becomes exercisable in equal monthly installments over a four-year period beginning on the exercisable date, and expires on January 7, 2034. The exercise price reflects conversion from Swiss francs at an exchange rate of $1.2769 per CHF 1.00 as of March 12, 2026.
Addex Therapeutics Ltd. Chief Executive Officer Timothy Mark Dyer filed an initial insider ownership report. He reports direct ownership of 16,848,979 shares of common stock listed on SIX Swiss Exchange. This filing does not show new purchases or sales; it establishes his existing position.
Dyer also holds stock options giving the right to buy 3,369,796 shares of common stock at an exercise price of $0.064 per share. These options vest in equal monthly installments over four years starting on the exercisable date of January 8, 2024 and expire on January 7, 2034. The exercise price is shown in U.S. dollars based on a stated CHF-to-USD exchange rate as of March 12, 2026.
Addex Therapeutics Ltd. director Jason Raleigh Nunn filed an initial ownership report showing his existing stake in the company. He directly holds 219,561 shares of Common Stock listed on SIX Swiss Exchange and a stock option covering 50,000 shares of Common Stock.
The stock options have an exercise price of $0.0640 per share, become exercisable in equal monthly installments over a four-year period beginning on the exercise start date of January 8, 2024, and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a stated CHF-to-USD exchange rate.
Addex Therapeutics director Isaac Manke reported his initial holdings. He directly owns 219,561 shares of Common Stock listed on the SIX Swiss Exchange and holds stock options on 50,000 shares of Common Stock with a $0.064 exercise price.
The stock options began vesting in equal monthly installments over a four-year period starting on January 8, 2024 and expire on January 7, 2034. The exercise price is reported in U.S. dollars based on a CHF-to-USD exchange rate as of March 12, 2026.